Leucemia mielóide aguda em crianças e adolescentes em instituições Brasileiras: realidade e desafios

Authors

  • Ana Luiza de Melo Rodrigues Department of Pediatric Oncology and Bone Marrow Transplant, Erasto Gaertner Hospital, Curitiba – PR, Brazil https://orcid.org/0000-0002-2346-7194
  • Luana Lenzi Department of Clinical Analysis, Federal University of Paraná, Curitiba - PR, Brazil https://orcid.org/0000-0002-4829-1703
  • Lisa Lee-Jones Department of Life Sciences, Manchester Metropolitan University, Manchester, United Kingdom https://orcid.org/0000-0003-1255-3545
  • Alayde Vieira Wanderley Department of Pediatric Oncology, Hospital Oncológico Octávio Lobo, Belém – PA, Brazil
  • Ana Maria Marinho Da Silva Department of Pediatric Oncology, Aristides Maltez Hospital, Salvador – BA, Brazil
  • Cinthya Rocha De Carvalho Department of Pediatric Oncology, Institute of Integral Medicine Professor Fernando Figueira – IMIP, Recife – PE, Brazil
  • Juliana Teixeira Costa Department of Pediatric Oncology, Martagão Gesteira Hospital, Salvador – BA, Brazil
  • Cláudio Galvão De Castro Junior Department of Pediatric Oncology, Santo Antonio Children's Hospital, Porto Alegre – RS, Brazil
  • Maria Lucia De Martino Lee Brazilian Childhood Leukemia Treatment Group (GBTLI) - Coordinator
  • Mecneide Mendes Lins Department of Pediatric Oncology, Institute of Integral Medicine Professor Fernando Figueira – IMIP, Recife – PE, Brazil
  • Patrick Rezende Godinho Department of Pediatric Oncology, Fundação Pio XII - Amor da Amazônia Hospital, Porto Velho – RO, Brazil
  • Raul Correa Ribeiro Department of Oncology and Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis - TN, USA https://orcid.org/0000-0002-9956-5647

DOI:

https://doi.org/10.46765/2675-374X.2020v2n1p77-86

Keywords:

Pediatric AML. HSCT. Brazil

Abstract

Objective: To describe the outcome of acute myeloid leukemia (AML) among children treated in Brazilian institutions. Methods: A structured online questionnaire was sent to pediatric oncologists affiliated to the Brazilian Society of Pediatric Oncology. The physicians and institutions were unidentified. Results: One hundred and four pediatric oncologists in all Brazilian regions answered the questionnaire. The treatment-related mortality rate was reported to be higher than 30% by 29.8% of the participants. Difficulty in accessing the intensive care unit (ICU) was reported by 54.8%. About 85% had access to cytogenetics, 78% to molecular testing, 94% to the measurement of residual disease by flow cytometry. About 90% of participants reported access to HSCT, but 86% of them had difficulties in providing HSCT timely. About 95% of the respondents indicated the need to create a national treatment protocol, and 89.4% are willing to collaborate with a national study group. Conclusion: Our study demonstrated large gaps in the treatment of pediatric AML in Brazil. To improve outcome, a national protocol will have to consider the regional differences and adapt the management according to the local resources.

Downloads

Published

10/14/2020

How to Cite

de Melo Rodrigues, A. L., Lenzi, L., Lee-Jones, L., Vieira Wanderley, A., Marinho Da Silva, A. M., Rocha De Carvalho, C., Teixeira Costa, J., Galvão De Castro Junior, C., De Martino Lee, M. L., Mendes Lins, M., Rezende Godinho, P., & Correa Ribeiro, R. (2020). Leucemia mielóide aguda em crianças e adolescentes em instituições Brasileiras: realidade e desafios. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 1(3), 77–86. https://doi.org/10.46765/2675-374X.2020v2n1p77-86